Figure 1.

Schematic representation of the process of selecting starting doses in a first-in-human trial of a MAB. Eff1–3 could be predicted human effects such as biomarkers, toxicological effects, etc. HED, human equivalent no adverse event level dose; RO, receptor occupancy